Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sven de Vos

Showing results (51-60 of 69) with videos related to

Pageof 7
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2025
Allogeneic Chimeric Antigen Receptor T-Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical StudiesFrederick L Locke, Javier L Munoz, Michael T Tees, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2017
Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell LymphomaJohn P Leonard, Kathryn S Kolibaba, James A Reeves, et al.
Blood|September 8, 2025
Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphomaLorenzo Falchi, Anna Sureda, Sirpa Leppä, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2007
Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphomaMichael J Robertson, Brad S Kahl, Julie M Vose, et al.
Haematologica|March 5, 2026
Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma: results from the EPCORE NHL-2 trialPau Abrisqueta, Yasmin H Karimi, Daniel Morillo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2025
Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin LymphomaSattva S Neelapu, Julio C Chavez, Alison R Sehgal, et al.
Blood|February 4, 2021
A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphomaFranck Morschhauser, Pierre Feugier, Ian W Flinn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 12, 2019
DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin LymphomaIan W Flinn, Carole B Miller, Kirit M Ardeshna, et al.
The New England Journal of Medicine|January 24, 2014
PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphomaAjay K Gopal, Brad S Kahl, Sven de Vos, et al.
Blood|October 25, 2023
Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)Sattva S Neelapu, Julio C Chavez, Alison R Sehgal, et al.
Pageof 7

Showing results (51-60 of 69) with videos related to

Sort By:
Pageof 7
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2025
Allogeneic Chimeric Antigen Receptor T-Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical StudiesFrederick L Locke, Javier L Munoz, Michael T Tees, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2017
Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell LymphomaJohn P Leonard, Kathryn S Kolibaba, James A Reeves, et al.
Blood|September 8, 2025
Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphomaLorenzo Falchi, Anna Sureda, Sirpa Leppä, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2007
Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphomaMichael J Robertson, Brad S Kahl, Julie M Vose, et al.
Haematologica|March 5, 2026
Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma: results from the EPCORE NHL-2 trialPau Abrisqueta, Yasmin H Karimi, Daniel Morillo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2025
Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin LymphomaSattva S Neelapu, Julio C Chavez, Alison R Sehgal, et al.
Blood|February 4, 2021
A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphomaFranck Morschhauser, Pierre Feugier, Ian W Flinn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 12, 2019
DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin LymphomaIan W Flinn, Carole B Miller, Kirit M Ardeshna, et al.
The New England Journal of Medicine|January 24, 2014
PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphomaAjay K Gopal, Brad S Kahl, Sven de Vos, et al.
Blood|October 25, 2023
Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)Sattva S Neelapu, Julio C Chavez, Alison R Sehgal, et al.
Pageof 7